160 related articles for article (PubMed ID: 37965074)
1. Pretreatment Neutrophil-to-Lymphocyte Ratio as Prognostic Biomarkers in Patients with Unresectable Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab.
Xiao Y; Zhu G; Xie J; Luo L; Deng W; Lin L; Tao J; Hu Z; Shan R
J Hepatocell Carcinoma; 2023; 10():2049-2058. PubMed ID: 37965074
[TBL] [Abstract][Full Text] [Related]
2. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
[TBL] [Abstract][Full Text] [Related]
3. Comparative Analysis of Lenvatinib and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multi-Center, Propensity Score Study.
Lee J; Han JW; Sung PS; Lee SK; Yang H; Nam HC; Yoo SH; Lee HL; Kim HY; Lee SW; Kwon JH; Jang JW; Kim CW; Nam SW; Oh JS; Chun HJ; Bae SH; Choi JY; Yoon SK
J Clin Med; 2021 Sep; 10(18):. PubMed ID: 34575160
[TBL] [Abstract][Full Text] [Related]
4. Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study.
Li Q; Cao M; Yuan G; Cheng X; Zang M; Chen M; Hu X; Huang J; Li R; Guo Y; Ruan J; Chen J
Front Oncol; 2022; 12():809709. PubMed ID: 35280760
[TBL] [Abstract][Full Text] [Related]
5. Postprogression treatment of lenvatinib plus PD-1 inhibitor in advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.
An C; Fu Y; Li W; Zuo M; Wu P
Cancer; 2023 Jul; 129(14):2235-2244. PubMed ID: 37029486
[TBL] [Abstract][Full Text] [Related]
6. Analysis on Efficacy of Hepatic Artery Infusion Chemotherapy with or without Lenvatinib for Unresectable Hepatocellular Carcinoma.
Yuan W; Yue W; Wen H; Wang X; Wang Q
Eur Surg Res; 2023; 64(2):268-277. PubMed ID: 36812900
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma.
Ma KP; Fu JX; Duan F; Wang MQ
World J Gastrointest Oncol; 2024 Apr; 16(4):1236-1247. PubMed ID: 38660650
[TBL] [Abstract][Full Text] [Related]
8. Neutrophil-to-lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib.
Tada T; Kumada T; Hiraoka A; Michitaka K; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Yasuda S; Toyoda H; Fukunishi S; Ohama H; Kawata K; Nakamura S; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y
Liver Int; 2020 Apr; 40(4):968-976. PubMed ID: 32064740
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of hepatic arterial infusion chemotherapy combined with transarterial embolization for unresectable hepatocellular carcinoma: A propensity score-matching cohort study.
Guo W; Gao J; Zhuang W; Wu Z; Li B; Chen S
JGH Open; 2020 Jun; 4(3):477-483. PubMed ID: 32514457
[TBL] [Abstract][Full Text] [Related]
10. Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Tislelizumab with or Without Transhepatic Arterial Embolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and High Tumor Burden: A Multicenter Retrospective Study.
Chen S; Shi F; Wu Z; Wang L; Cai H; Ma P; Zhou Y; Mai Q; Wang F; Tang S; Zhuang W; Lai J; Chen X; Chen H; Guo W
J Hepatocell Carcinoma; 2023; 10():1209-1222. PubMed ID: 37533600
[TBL] [Abstract][Full Text] [Related]
11. Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma.
Xu YJ; Lai ZC; He MK; Bu XY; Chen HW; Zhou YM; Xu L; Wei W; Zhang YJ; Chen MS; Guo RP; Shi M; Li QJ
Technol Cancer Res Treat; 2021; 20():15330338211063848. PubMed ID: 34898313
[No Abstract] [Full Text] [Related]
12. Modified Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab for Advanced HCC: Two Case Reports.
Tian Y; Jin W; Sun H; Jin D; Kang D; Li Z; Piao L
J Hepatocell Carcinoma; 2023; 10():1587-1593. PubMed ID: 37791067
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study.
Chen S; Xu B; Wu Z; Wang P; Yu W; Liu Z; Huang X; Wu Y; Li T; Guo W
BMC Cancer; 2021 Oct; 21(1):1126. PubMed ID: 34670506
[TBL] [Abstract][Full Text] [Related]
14. The Prognostic Value of Inflammation Factors in Hepatocellular Carcinoma Patients with Hepatic Artery Interventional Treatments: A Retrospective Study.
Guo L; Ren H; Pu L; Zhu X; Liu Y; Ma X
Cancer Manag Res; 2020; 12():7173-7188. PubMed ID: 33061563
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of transarterial chemoembolization combined with lenvatinib and camrelizumab in patients with BCLC-defined stage C hepatocellular carcinoma.
Wu J; Zeng J; Wang H; Huo Z; Hou X; He D
Front Oncol; 2023; 13():1244341. PubMed ID: 37916160
[TBL] [Abstract][Full Text] [Related]
16. Blood neutrophil to lymphocyte ratio as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy.
Terashima T; Yamashita T; Iida N; Yamashita T; Nakagawa H; Arai K; Kitamura K; Kagaya T; Sakai Y; Mizukoshi E; Honda M; Kaneko S
Hepatol Res; 2015 Sep; 45(9):949-959. PubMed ID: 25319848
[TBL] [Abstract][Full Text] [Related]
17. Combination of psoas muscle mass index and neutrophil/lymphocyte ratio as a prognostic predictor for patients undergoing nonsurgical hepatocellular carcinoma therapy.
Sugama Y; Miyanishi K; Osuga T; Tanaka S; Hamaguchi K; Ito R; Sakamoto H; Kubo T; Ohnuma H; Murase K; Takada K; Kobune M; Kato J
JGH Open; 2021 Dec; 5(12):1335-1343. PubMed ID: 34950776
[TBL] [Abstract][Full Text] [Related]
18. Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis.
Fu Y; Peng W; Zhang W; Yang Z; Hu Z; Pang Y; Hu D; Chen J; Wang J; Zhou Z; Xu L; Chen M; Zhang Y
J Gastroenterol; 2023 Apr; 58(4):413-424. PubMed ID: 36894804
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Lenvatinib Combined With PD-1 Inhibitors Plus TACE for Unresectable Hepatocellular Carcinoma Patients in China Real-World.
Li X; Fu Z; Chen X; Cao K; Zhong J; Liu L; Ding N; Zhang X; Zhai J; Qu Z
Front Oncol; 2022; 12():950266. PubMed ID: 35860582
[TBL] [Abstract][Full Text] [Related]
20. Comparison Between Portal Vein Perfusion Chemotherapy and Neoadjuvant Hepatic Arterial Infusion Chemotherapy for Resectable Intermediate to Advanced Stage Hepatocellular Carcinoma.
Pan Y; Mei J; Chen J; Zhang D; Wang J; Wang X; Yi M; Zhou Z; Zhang Y; Chen M; Guo R; Xu L
Ann Surg Oncol; 2022 Mar; 29(3):2016-2029. PubMed ID: 34637058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]